Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of sufentanil tablet (ST) 30 mcg in the management of
moderate-to-severe acute pain in patients in an emergency room (ER) setting.
Phase:
Phase 3
Details
Lead Sponsor:
AcelRx Pharmaceuticals, Inc.
Collaborators:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command